MedTrace Logo

Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia

NCT05638763 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-12-06

No results posted yet for this study

Summary

This phase 2 single-arm study aims to demonstrate the efficacy of strong cytochrome inhibition with ketoconazole to reduce dasatinib dosage for adults with chronic myelogenous leukemia. Researchers will describe response rates and adverse events.

Conditions

  • Chronic Myeloid Leukemia, Chronic Phase

Interventions

DRUG

Dasatinib Pill

Patients will receive half pill of dasatinib 50mg (25mg/day, orally) for one year

DRUG

Ketoconazole Pill

Patients will receive ketoconazole 200mg two times a day, orally, for one year.

Sponsors & Collaborators

  • Fernando De la Garza Salazar

    collaborator UNKNOWN

  • Hospital Universitario Dr. Jose E. Gonzalez

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-30
Primary Completion
2024-11-30
Completion
2024-11-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05638763 on ClinicalTrials.gov